The relationship between GLP-1 receptor agonists and vision problems centres primarily on diabetic retinopathy , a complication of diabetes affecting the blood vessels in the retina
Bogh AF, Jensen SB, Juhl CR, et al
How Many Adults with Private Health Insurance Could Use GLP-1 Drugs More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis
Here is a general breakdown of coverage likelihood by plan type: The most reliable way to check is to log into your Aetna member portal, navigate to the pharmacy section, and search for the specific drug name
Retin Eye Res
Possible causes: dead space accumulation (discussed above), inaccurate water volume at reconstitution (more water means more dilute, means more volume per dose, means fewer doses from the same amount of peptide), or air in the vial displacing solution